The Role of Vascular Cell Adhesion Molecule-1 in Tumor Immune Evasion
- 1 July 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (13), 6003-6006
- https://doi.org/10.1158/0008-5472.can-07-1543
Abstract
Tumor immune escape is a critical trait of cancer but the mechanisms involved have yet to fully emerge. One recent study has shown that tumor cells can escape T-cell immunity by overexpressing the endothelial cell adhesion molecule vascular cell adhesion molecule-1 (VCAM-1), which normally mediates leukocyte extravasion to sites of tissue inflammation. Renal cell carcinoma (RCC) was identified as one tumor type where VCAM-1 is commonly highly overexpressed. Together, our findings suggest that RCCs might exploit VCAM-1 overexpression for immune escape. [Cancer Res 2007;67(13):6003–6]Keywords
This publication has 16 references indexed in Scilit:
- Endothelial Cell Adhesion Molecules and Cancer ProgressionCurrent Medicinal Chemistry, 2007
- Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejectionCancer Cell, 2004
- Cell adhesion and signalling by cadherins and Ig-CAMs in cancerNature Reviews Cancer, 2004
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003
- Paxillin Binding to the α4 Integrin Subunit Stimulates LFA-1 (Integrin αLβ2)-Dependent T Cell Migration by Augmenting the Activation of Focal Adhesion Kinase/Proline-Rich Tyrosine Kinase-2The Journal of Immunology, 2003
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationNature, 2002
- α4 integrins and the immune responseImmunological Reviews, 2002
- Binding of paxillin to α4 integrins modifies integrin-dependent biological responsesNature, 1999
- Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.1996
- Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.Proceedings of the National Academy of Sciences, 1995